Chad Swanson PhD

Dr. Swanson is currently Director of Neuroscience Clinical Development, Neurology Business Group, Neurodegenerative Diseases at Eisai, Inc, where he serves as the study director for a large, highly novel Phase 2b proof of concept study of a monoclonal antibody (BAN2401-G000-201) in Early AD. Before joining Eisai, Dr. Swanson held clinical research positions in neurodegeneration at Merck and Schering Plough. Prior to his tenure in clinical research and development, Dr. Swanson was Senior Scientist and US Head of Neurochemistry, Target Discovery and Assessment, at Lundbeck, Inc, where he led a number of discovery programs and ran a lab devoted to discovery and preclinical research in psychiatric disease. Dr. Swanson received his Ph.D. from the Medical University of South Carolina in Physiology and Neuroscience, and his BS degree from the University of Wisconsin – Madison in Zoology with Neurobiology emphasis.